BioCatalyst

ABBV-RGX-314, ABBV-RGX-314, Ranibizumab (LUCENTIS®) — catalyst calendar

1 verified catalyst event(s) referencing ABBV-RGX-314, ABBV-RGX-314, Ranibizumab (LUCENTIS®), each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere
Phase 2/3 · AMD, nAMD
 ABBV AbbVie Inc. ABBV-RGX-314, ABBV-RGX-314, Ranibizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.